Plasma Metabolomic and Lipidomic Profiling in Early-Stage Psychosis

Metabolic alterations in early-stage psychosis may provide insights into disease pathophysiology and potential biomarkers. We performed targeted metabolomic and lipidomic profiling of plasma samples from 31 patients with early-stage psychosis (onset within 24 months) and 22 healthy controls using a liquid chromatography-mass spectrometry (LC-MS) platform. Of 523 compounds analyzed, 16 (3 metabolites, 13 lipids) were significantly altered in patients compared with controls, with a significant enrichment of glycerolipids (69%). Within patients, glycerolipids significantly correlated with symptom severity and cognitive performance. These findings highlight the involvement of glycerolipid metabolism in early psychosis and clinical outcomes.